Serodus ASA Stock

Stocks

17-01-02	Serodus : Primary endpoint reached by SER150 Phase 2a study in Diabetic Nephropathy.	PU
16-12-08	Serodus : Q&A delisting from Oslo Axess	PU
16-11-23	Serodus : Extraordinary general meeting held	PU
16-11-23	Serodus : Viggo Harboe Holding 2006 ApS announces results of voluntary offer	PU
16-11-02	Serodus : Viggo Harboe Holding 2006 Aps Launces voluntary offer for outstanding shares in Serodus ASA – Acceptance period starting 31 October 2016	PU

1 day

-5.56%

Manager	Title	Age	Since
Arnstein Gunnestad Endresen CEO	Chief Executive Officer	73	2022-12-31
Henrik Mordhorst DFI	Director of Finance/CFO	-	2019-09-30
Daniel Capion PRN	Corporate Officer/Principal	-	2020-12-31

Director	Title	Age	Since
Søren Elmann Ingerslev CHM	Chairman	-	2016-12-31
Terri Sebree BRD	Director/Board Member	68	2014-03-31
Viggo Gunnersen Harboe BRD	Director/Board Member	80	2021-12-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SERODUS ASA	-5.56%	+7.94%	-	-	0
WUXI APPTEC CO., LTD.	-1.79%	-3.82%	+38.74%	+91.90%	69.02B
ARGENX SE	-2.06%	-0.18%	+41.53%	+88.17%	66.32B
INSMED INCORPORATED	-0.15%	+7.13%	-10.90%	+381.57%	27.66B
BIONTECH SE	+1.30%	+2.69%	+1.28%	-14.08%	25.84B
WUXI BIOLOGICS (CAYMAN) INC.	-3.00%	-2.61%	+34.45%	+11.39%	26.54B
GENMAB A/S	-1.46%	+0.42%	+24.07%	-18.70%	20.4B
PHARMAESSENTIA CORPORATION	-2.96%	-16.03%	+213.13%	+375.00%	17.63B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.49%	-6.69%	-4.69%	+539.74%	15.15B
EXELIXIS, INC.	-0.14%	+8.45%	+57.97%	+165.15%	14.65B
Average	-1.73%	-0.66%	+43.95%	+180.02%	31.47B
Weighted average by Cap.	-1.47%	-0.45%	+39.19%	+139.51%

Employees

Sector